Clinical Trial: A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07247110) titled 'A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)' on Nov. 19.

Brief Summary: Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Malignant Neoplasm

Intervention: DRUG: MK-4716

Oral administration

BIOLOGICAL: Pembrolizumab

Intravenous administration

BIOLOGICAL: Cetuximab

Intravenous administration

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Merck Sharp & Doh...